Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents

Maisa N. Feghali; Steve N. Caritis; Janet M. Catov; Christina M. Scifres

doi:10.1055/s-0036-1597625

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2017; 34(07): 697-704
DOI: 10.1055/s-0036-1597625

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents

Authors

Maisa N. Feghali

¹Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Steve N. Caritis

¹Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Janet M. Catov

¹Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Christina M. Scifres

²Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

Abstract

Objective There is limited data regarding the use of oral hypoglycemic agents (OHAs) in pregnant women with type 2 diabetes mellitus (T2DM).

Study Design This was a retrospective cohort study of women with T2DM who were treated with OHA or insulin from the first trimester onward. Bivariate and multivariate logistic regression analyses were used to compare pregnancy outcomes in women treated with OHA to those treated with insulin.

Results One-third (67/198) of women were treated with OHA. Women treated with OHA had a shorter disease duration (4.4 vs. 6.8 years; p = 0.001), were more likely to have a normal prepregnancy body mass index, and had less gestational weight gain (GWG; 22.4 vs. 30.4 lbs; p = 0.005). A lower GWG was noted in obese women treated with OHA (19.9 ± 18.6 vs. 28.3 ± 17.7 pounds; p = 0.008). First-trimester hemoglobin A1c values were lower with OHAs, but second- and third-trimester values were similar. Among women who started pregnancy using OHA, 37/67 (55.2%) remained on OHA at delivery. Pregnancy outcomes did not differ between women who received OHA and those treated with insulin.

Conclusion OHA treatment is more likely in women with T2DM who begin pregnancy with less severe disease, and use of OHA may be associated with decreased GWG.

Keywords

pregnancy - treatment - oral hypoglycemic agents - type 2 diabetes mellitus

Volltext

Referenzen

References
1 ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105 (3) 675-685
2 Standards of Medical Care in Diabetes—2016: Summary of Revisions. Diabetes Care 2016; 39 (Suppl. 01) S4-S5
3 Kalra B, Gupta Y, Singla R, Kalra S. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. N Am J Med Sci 2015; 7 (1) 6-12
4 Inzucchi SE, Majumdar SK. Current therapies for the medical management of diabetes. Obstet Gynecol 2016; 127 (4) 780-794
5 Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin Jr DK, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol 2014; 123 (6) 1177-1184
6 Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol 2006; 107 (6) 1303-1309
7 Amin M, Suksomboon N, Poolsup N, Malik O. Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis. Clin Drug Investig 2015; 35 (6) 343-351
8 Rasmussen KM, Catalano PM, Yaktine AL. New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. Curr Opin Obstet Gynecol 2009; 21 (6) 521-526
9 Scifres CM, Feghali MN, Althouse AD, Caritis SN, Catov JM. Effect of excess gestational weight gain on pregnancy outcomes in women with type 1 diabetes. Obstet Gynecol 2014; 123 (6) 1295-1302
10 Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87 (2) 163-168
11 Rasmussen KM, Yaktine AL. Weight Gain during Pregnancy: Reexamining the Guidelines. Washington, DC: National Academies Press; 2009
12 Biesenbach GB, Pieringer H. Gender-associated differences in weight gain, insulin requirement and metabolic control in newly insulin-treated type 2 diabetic patients with secondary sulfonylurea failure—a one-year observation. Clin Med Insights 2009; 2: 75-80
13 Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. Am J Physiol Gastrointest Liver Physiol 2007; 293 (1) G1-G4
14 Coppack SW, Patel JN, Lawrence VJ. Nutritional regulation of lipid metabolism in human adipose tissue. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl. 02) S202-S214
15 Dimitriadis G, Mitrou P, Lambadiari V , et al. Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrinol Metab 2006; 91 (3) 1112-1118
16 Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002; 45 (9) 1201-1210
17 Yee LM, Cheng YW, Inturrisi M, Caughey AB. Effect of gestational weight gain on perinatal outcomes in women with type 2 diabetes mellitus using the 2009 Institute of Medicine guidelines. Am J Obstet Gynecol 2011; 205 (3) 257.e1-257.e6
18 Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350: h102
19 De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011; 157 (1) 63-66
20 Glueck CJ, Goldenberg N, Pranikoff J, Khan Z, Padda J, Wang P. Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Curr Med Res Opin 2013; 29 (1) 55-62
21 Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19 (6) 1323-1330
22 Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17 (11) 2858-2864
23 Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. Am J Public Health 2005; 95 (9) 1545-1551
24 Metformin in Women With Type 2 Diabetes in Pregnancy Trial (MiTy). Available at https://clinicaltrials.gov/ct2/show/NCT01353391 . Accessed on October 15, 2016